NDA 021341 · Gd Searle
Bextra
Valdecoxib · Oral
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 24, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Nov 16, 2001
Approved uses
2
Original approval plus efficacy supplements
Registered trials
30
12 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2004 Supplement 3 · Efficacy LetterLabel
- Nov 16, 2001 Original approval · Type 1 - New Molecular Entity NovelReviewLabelOther Important Information from FDA
2 products under this application
- BEXTRA · VALDECOXIB 20MG · TABLET, ORAL · Discontinued
- BEXTRA · VALDECOXIB 10MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Valdecoxib" as an intervention, any sponsor and status, largest first.
- A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass SurgeryPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00636064 · 1,671 participants · Start Jan 2003
Drug: Parecoxib Sodium/Valdecoxib; Placebo/Valdecoxib · For: Pain
Sites: Fairhope, Alabama; Mobile, Alabama; Tucson, Arizona · 206 sites in all
- Effect Study of Parecoxib to Treat Emergence Delirium and Postoperative PainPivotal-lookingStatus unknown
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT01221025 · 900 participants (planned) · Start Sep 2010 · Primary completion Dec 2011
Drug: Parecoxib · For: Emergence Delirium; Postoperative Pain
Sites: Guangzhou, China
- A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery PainPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00661635 · 490 participants · Start Nov 2002
Drug: placebo; valdecoxib and 1 more · For: Laparoscopic Cholecystectomy; Pain
Sites: Birmingham, Alabama; Daphne, Alabama; Fairhope, Alabama · 65 sites in all
PfizerPfizer (PFE)
NCT00650455 · 489 participants · Start Feb 2003 · Primary completion Jan 2005
Drug: valdecoxib; naproxen and 1 more · For: Arthritis, Rheumatoid
Sites: Birmingham, Alabama; Huntsville, Alabama; Glendale, Arizona · 55 sites in all
PfizerPfizer (PFE)
NCT00650039 · 488 participants · Start Mar 2004
Drug: placebo; valdecoxib and 1 more · For: Pain
Sites: Birmingham, Alabama; Northport, Alabama; Glendale, Arizona · 81 sites in all
- A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00092300 · 450 participants · Start May 2002 · Primary completion Sep 2002
Drug: MK0966, rofecoxib; Comparator: valdecoxib · For: Postoperative Pain
- Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy SurgeryPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00683137 · 450 participants · Start Oct 2002
Drug: valdecoxib; valdecoxib and 1 more · For: Pain; Hallux Valgus
Sites: Chandler, Arizona; Glendale, Arizona; Mesa, Arizona · 89 sites in all
- A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00650624 · 416 participants · Start Jun 2003
Drug: valdecoxib; valdecoxib and 2 more · For: Osteoarthritis, Knee
Sites: Funabashi, Japan; Sakura, Japan; Chikushi-gun, Japan · 22 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Relative thromboembolic risks associated with COX-2 inhibitors.
Jones SC · Ann Pharmacother 2005 · Meta-Analysis, Review
- Oral herbal therapies for treating osteoarthritis.
Cameron M, Chrubasik S · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles.
Giorgi M, Saccomanni G, Del Carlo S, et al. · Vet J 2012 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Valdecoxib does not interfere with the CYP2D6 substrate metoprolol.
Werner U, Lamprecht C, Werner D, et al. · Int J Clin Pharmacol Ther 2006 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization.
Sarapa N, Britto MR, Cotton B, et al. · J Clin Pharmacol 2003 · Clinical Trial, Controlled Clinical Trial
Sponsor: Gd Searle
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.